YAP1 and neoplasm: Ribociclib (LEE011) is a selective CDK4/6 inhibitor used in aggressive thyroid cancer via oral administration in a PDX tumor model.366 Ribociclib promoted the sensitivity of radiation-resistant esophageal cancer cells by inhibiting YAP1 expression.